Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma

Background: Multiple myeloma is a disease of the elderly. However, 40% of patients are diagnosed before 65 years old. Outcomes regarding age as a prognostic factor in MM are heterogeneous. Method: We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patient...

Full description

Bibliographic Details
Authors: Bove, Virginia, Garrido, David, Riva, Eloísa
Format: article
Status:Published version
Publication Date:2021
Country:Uruguay
Institution:Universidad de la República
Repository:COLIBRI
Language:English
OAI Identifier:oai:colibri.udelar.edu.uy:20.500.12008/55483
Online Access:https://hdl.handle.net/20.500.12008/55483
Access Level:Open access
Keyword:Age
Multiple myeloma
Survival
Transplantation
TRASPLANTE DE CÉLULAS
ADULTO JOVEN
MIELOMA MÚLTIPLE
TASA DE SUPERVIVENCIA
id UY_5fa3ffd1742c4a2f52ea7fed4dcc5723
oai_identifier_str oai:colibri.udelar.edu.uy:20.500.12008/55483
network_acronym_str UY
network_name_str Uruguay
repository_id_str
dc.title.none.fl_str_mv Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
title Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
spellingShingle Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
Bove, Virginia
Age
Multiple myeloma
Survival
Transplantation
TRASPLANTE DE CÉLULAS
ADULTO JOVEN
MIELOMA MÚLTIPLE
TASA DE SUPERVIVENCIA
title_short Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
title_full Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
title_fullStr Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
title_full_unstemmed Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
title_sort Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
dc.creator.none.fl_str_mv Bove, Virginia
Garrido, David
Riva, Eloísa
author Bove, Virginia
author_facet Bove, Virginia
Garrido, David
Riva, Eloísa
author_role author
author2 Garrido, David
Riva, Eloísa
author2_role author
author
dc.contributor.filiacion.none.fl_str_mv Bove Virginia, Hospital Central de las Fuerzas Armadas (Uruguay)
Garrido David, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas
Riva Eloísa, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas; Hospital Central de las Fuerzas Armadas (Uruguay)
dc.subject.es.fl_str_mv Age
Multiple myeloma
Survival
Transplantation
topic Age
Multiple myeloma
Survival
Transplantation
TRASPLANTE DE CÉLULAS
ADULTO JOVEN
MIELOMA MÚLTIPLE
TASA DE SUPERVIVENCIA
dc.subject.other.es.fl_str_mv TRASPLANTE DE CÉLULAS
ADULTO JOVEN
MIELOMA MÚLTIPLE
TASA DE SUPERVIVENCIA
description Background: Multiple myeloma is a disease of the elderly. However, 40% of patients are diagnosed before 65 years old. Outcomes regarding age as a prognostic factor in MM are heterogeneous. Method: We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. Main results: The frequency of multiple myeloma in those younger than 66 years was 53.2%. Younger patients presented with a more aggressive disease, more advanced Durie-Salmon stage (85.3% vs 73.5%; p=0.013), extramedullary disease (12.7% vs 0%; p<0.001), osteolytic lesions (78.7% vs 57.6%; p<0.001) and bone plasmacytoma (25.3% vs 11.4%; p=0.003). In spite of this, the overall response rate was similar between groups (80.6% vs 81.4%; p=0.866). The overall survival was significantly longer in young patients (median, 65 months vs 41 months; p=0.001) and higher in those who received autologous hematopoietic stem cell transplantation. The main cause of death was disease progression in both groups. Multivariable analysis revealed that creatinine ≥2mg/dl, extramedullary disease, ≤very good partial remission and non-autologous hematopoietic stem cell transplantation are independent risk factors for shorter survival. Conclusion: Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation.
publishDate 2021
dc.date.issued.none.fl_str_mv 2021
dc.date.accessioned.none.fl_str_mv 2026-06-12T14:14:21Z
dc.date.available.none.fl_str_mv 2026-06-12T14:14:21Z
dc.type.es.fl_str_mv Artículo
dc.type.none.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.citation.es.fl_str_mv Bove V, Garrido D y Riva E. Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma. Hematology Transfusion and Cell Therapy [en línea]. 2021;43(3):295-302
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12008/55483
dc.identifier.doi.none.fl_str_mv 10.1016/j.htct.2020.06.014
dc.identifier.eissn.none.fl_str_mv 2531-1387
identifier_str_mv Bove V, Garrido D y Riva E. Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma. Hematology Transfusion and Cell Therapy [en línea]. 2021;43(3):295-302
10.1016/j.htct.2020.06.014
2531-1387
url https://hdl.handle.net/20.500.12008/55483
dc.language.iso.none.fl_str_mv en
eng
language_invalid_str_mv en
language eng
dc.relation.none.fl_str_mv Hematology, Transfusion and Cell Therapy. 2021;43(3):295-302
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.license.none.fl_str_mv Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv Licencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)
dc.format.extent.es.fl_str_mv 8 p.
dc.format.mimetype.es.fl_str_mv application/pdf
dc.publisher.es.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:COLIBRI
instname:Universidad de la República
instacron:Universidad de la República
instname_str Universidad de la República
instacron_str Universidad de la República
institution Universidad de la República
reponame_str COLIBRI
collection COLIBRI
bitstream.url.fl_str_mv http://localhost:8080/xmlui/bitstream/20.500.12008/55483/5/license.txt
http://localhost:8080/xmlui/bitstream/20.500.12008/55483/2/license_url
http://localhost:8080/xmlui/bitstream/20.500.12008/55483/3/license_text
http://localhost:8080/xmlui/bitstream/20.500.12008/55483/4/license_rdf
http://localhost:8080/xmlui/bitstream/20.500.12008/55483/1/Young+age+and+autologous+stem+cell+transplantation.pdf
bitstream.checksum.fl_str_mv 6429389a7df7277b72b7924fdc7d47a9
a006180e3f5b2ad0b88185d14284c0e0
51b36ee03fc10a96e37c6461d71cd071
d62648cf14c1e37917d392ac87012955
578d6c85814b75c9edc7b924a4e3dfa2
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv COLIBRI - Universidad de la República
repository.mail.fl_str_mv karina.camps@seciu.edu.uy
_version_ 1870824038969901056
spelling Bove Virginia, Hospital Central de las Fuerzas Armadas (Uruguay)Garrido David, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de ClínicasRiva Eloísa, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas; Hospital Central de las Fuerzas Armadas (Uruguay)2026-06-12T14:14:21Z2026-06-12T14:14:21Z2021Bove V, Garrido D y Riva E. Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma. Hematology Transfusion and Cell Therapy [en línea]. 2021;43(3):295-302https://hdl.handle.net/20.500.12008/5548310.1016/j.htct.2020.06.0142531-1387Background: Multiple myeloma is a disease of the elderly. However, 40% of patients are diagnosed before 65 years old. Outcomes regarding age as a prognostic factor in MM are heterogeneous. Method: We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. Main results: The frequency of multiple myeloma in those younger than 66 years was 53.2%. Younger patients presented with a more aggressive disease, more advanced Durie-Salmon stage (85.3% vs 73.5%; p=0.013), extramedullary disease (12.7% vs 0%; p<0.001), osteolytic lesions (78.7% vs 57.6%; p<0.001) and bone plasmacytoma (25.3% vs 11.4%; p=0.003). In spite of this, the overall response rate was similar between groups (80.6% vs 81.4%; p=0.866). The overall survival was significantly longer in young patients (median, 65 months vs 41 months; p=0.001) and higher in those who received autologous hematopoietic stem cell transplantation. The main cause of death was disease progression in both groups. Multivariable analysis revealed that creatinine ≥2mg/dl, extramedullary disease, ≤very good partial remission and non-autologous hematopoietic stem cell transplantation are independent risk factors for shorter survival. Conclusion: Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation.Submitted by Almiñana María Cecilia (marialminana@gmail.com) on 2026-06-11T17:25:57Z No. of bitstreams: 2 license_rdf: 27293 bytes, checksum: d62648cf14c1e37917d392ac87012955 (MD5) Young age and autologous stem cell transplantation.pdf: 2227056 bytes, checksum: 578d6c85814b75c9edc7b924a4e3dfa2 (MD5)Approved for entry into archive by Almiñana María Cecilia (marialminana@gmail.com) on 2026-06-12T12:21:27Z (GMT) No. of bitstreams: 2 license_rdf: 27293 bytes, checksum: d62648cf14c1e37917d392ac87012955 (MD5) Young age and autologous stem cell transplantation.pdf: 2227056 bytes, checksum: 578d6c85814b75c9edc7b924a4e3dfa2 (MD5)Made available in DSpace by Luna Fabiana (fabiana.luna@seciu.edu.uy) on 2026-06-12T14:14:21Z (GMT). No. of bitstreams: 2 license_rdf: 27293 bytes, checksum: d62648cf14c1e37917d392ac87012955 (MD5) Young age and autologous stem cell transplantation.pdf: 2227056 bytes, checksum: 578d6c85814b75c9edc7b924a4e3dfa2 (MD5) Previous issue date: 20218 p.application/pdfenengElsevierHematology, Transfusion and Cell Therapy. 2021;43(3):295-302Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)info:eu-repo/semantics/openAccessLicencia Creative Commons Atribución - No Comercial - Sin Derivadas (CC - By-NC-ND 4.0)AgeMultiple myelomaSurvivalTransplantationTRASPLANTE DE CÉLULASADULTO JOVENMIELOMA MÚLTIPLETASA DE SUPERVIVENCIAYoung age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myelomaArtículoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:COLIBRIinstname:Universidad de la Repúblicainstacron:Universidad de la RepúblicaBove, VirginiaGarrido, DavidRiva, EloísaLICENSElicense.txtlicense.txttext/plain; charset=utf-84267http://localhost:8080/xmlui/bitstream/20.500.12008/55483/5/license.txt6429389a7df7277b72b7924fdc7d47a9MD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-850http://localhost:8080/xmlui/bitstream/20.500.12008/55483/2/license_urla006180e3f5b2ad0b88185d14284c0e0MD52license_textlicense_texttext/html; charset=utf-835923http://localhost:8080/xmlui/bitstream/20.500.12008/55483/3/license_text51b36ee03fc10a96e37c6461d71cd071MD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-827293http://localhost:8080/xmlui/bitstream/20.500.12008/55483/4/license_rdfd62648cf14c1e37917d392ac87012955MD54ORIGINALYoung age and autologous stem cell transplantation.pdfYoung age and autologous stem cell transplantation.pdfapplication/pdf2227056http://localhost:8080/xmlui/bitstream/20.500.12008/55483/1/Young+age+and+autologous+stem+cell+transplantation.pdf578d6c85814b75c9edc7b924a4e3dfa2MD5120.500.12008/554832026-06-12 11:14:21.526oai:colibri.udelar.edu.uy:20.500.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Institucionalhttps://www.colibri.udelar.edu.uyUniversidad públicahttps://udelar.edu.uy/https://www.colibri.udelar.edu.uy/oai/requestkarina.camps@seciu.edu.uyUruguayopendoar:47712026-06-12T14:14:21COLIBRI - Universidad de la Repúblicafalse
score 15,812429

Similar Items